Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case

被引:31
作者
Heiss, S
Erdel, M
Gunsilius, E
Nachbaur, D
Tzankov, A [1 ]
机构
[1] Med Univ Innsbruck, Inst Pathol, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Med Genet Mol & Clin Pharmacol, A-6020 Innsbruck, Austria
[3] Univ Innsbruck, Dept Hematol & Oncol, A-6020 Innsbruck, Austria
关键词
myelodysplastic/myeloproliferative diseases; erythroleukemia; t(8; 9);
D O I
10.1016/j.humpath.2005.07.020
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We report on a patient fulfilling the diagnostic criteria of unclassifiable myelodysplastic/myeloproliferative diseases with prominent erythropoietic hyperplasia/dysplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24). The patient presented with B-symptoms, crythroblastemia, thrombopenia, marked eosinophilia, presence of myeloid precursors in the peripheral blood, and decreased erythropoietin level. Nodular peritrabecular polymorphous blasts, dysplastic megakaryocytes, and a diffuse argyrophilic fibrosis were detected in the trephine bone marrow biopsy. Immunohistochemically, the blasts stained positively for glycophorin C and hemoglobin A; the proliferation fraction was nearly 90% in the Ki-67 stain. Expression of the phosphorylated Janus kinase 2 was detected in almost all megakaryocytes and in isolated erythroblast islets, suggesting a probable activation of Janus kinase 2, the jak-2 gene being mapped on 9p24. Ten months after initial diagnosis, the disease progressed to frank acute erythroid leukemia. We report for the first time a myelodysplastic/myeloproliferative disease (erythroid preleukemia) accompanied by the specific chromosomal aberration t(8;9)(p23;p24), distinct histopathology, and clinical and laboratory symptoms, and progress to acute crythroid leukemia. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1148 / 1151
页数:4
相关论文
共 10 条
[1]   INTERLEUKIN-5 AND ITS RECEPTOR - A DRUG TARGET FOR EOSINOPHILIA ASSOCIATED WITH CHRONIC ALLERGIC DISEASE [J].
DEVOS, R ;
PLAETINCK, G ;
CORNELIS, S ;
GUISEZ, Y ;
VANDERHEYDEN, J ;
TAVERNIER, J .
JOURNAL OF LEUKOCYTE BIOLOGY, 1995, 57 (06) :813-819
[2]   The 8p11 myeloproliferative syndrome:: A distinct clinical entity caused by constitutive activation of FGFR1 [J].
Macdonald, D ;
Reiter, A ;
Cross, NCP .
ACTA HAEMATOLOGICA, 2002, 107 (02) :101-107
[3]  
MATSUSHIMA T, 1997, LEUKEMIA LYMPHOMA, V15, P491
[4]  
Mitelman F., 1995, SUPPLEMENT INT SYSTE
[5]   The erythropoietin receptor [J].
Mulcahy, L .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :19-23
[6]   Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia [J].
Peeters, P ;
Raynaud, SD ;
Cools, J ;
Wlodarska, I ;
Grosgeorge, J ;
Philip, P ;
Monpoux, F ;
VanRompaey, L ;
Baens, M ;
VandenBerghe, H ;
Marynen, P .
BLOOD, 1997, 90 (07) :2535-2540
[7]   The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs) [J].
Pellegrini, S ;
DusanterFourt, I .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 248 (03) :615-633
[8]   The 8; 21 translocation in leukemogenesis [J].
Peterson, LF ;
Zhang, DE .
ONCOGENE, 2004, 23 (24) :4255-4262
[9]   Association of JAK2 and STAT5 with erythropoietin receptors - Role of receptor phosphorylation in erythropoietin signal transduction [J].
Sawyer, ST ;
Penta, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (50) :32430-32437
[10]  
Vardiman JW, 2001, WHO CLASSIFICATION T, P47